Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma By Ogkologos - December 10, 2025 87 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II cohort of the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing MOST POPULAR Mom Spots Strange Glow In Daughter’s Eye While Looking At Photo,... April 24, 2019 Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer January 3, 2024 Cancer Screening Guidelines Often Lack Information on Potential Harms, Study Finds November 23, 2022 Blood Test for Early Detection of Cancer: Final Study Results Support... June 25, 2021 Load more HOT NEWS New study supports extending cervical screening intervals for people who test... Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2... Could A Form of Cell Death Enhance Cancer Immunotherapy? Hormone Therapy for Prostate Cancer? A Genetic Test Could Help Decide
